Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.37 |
| ▸ | OXTR | P30559 | 2/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CCR6 | P51684 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12923936 | 1.00 | KDM4C (0.40) | KDM4CACHETRPV1AVPR2AVPR1A | |
| SCHEMBL12923931 | 1.00 | KDM4C (0.40) | KDM4CACHETRPV1AVPR2AVPR1A | |
| SCHEMBL19719690 | 0.89 | AVPR2 (0.43) | KDM4CACHEAVPR2AVPR1AOXTR | |
| SCHEMBL27903243 | 0.80 | NOTUM (0.41) | ACHESIGMAR1PAX8GPR3NOTUM | |
| SCHEMBL30509271 | 0.80 | NOTUM (0.41) | ACHESIGMAR1PAX8GPR3NOTUM | |
| SCHEMBL13954014 | 0.79 | HTR1A (0.37) | KDM4CACHETRPV1SIGMAR1GPR3 | |
| SCHEMBL10173840 | 0.78 | NOTUM (0.43) | KDM4CACHETRPV1SIGMAR1GPR3 | |
| SCHEMBL7673078 | 0.78 | NOTUM (0.43) | KDM4CACHETRPV1SIGMAR1GPR3 | |
| SCHEMBL30274923 | 0.78 | NOTUM (0.43) | KDM4CACHETRPV1SIGMAR1GPR3 | |
| SCHEMBL29586069 | 0.77 | SLC6A2 (0.49) | KDM4CACHETRPV1SIGMAR1GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727594-B1 | NAPHTALENE COMPOUNDS TO TREAT ITCH | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-8809360-B2 | Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809360-B2 | Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| EP-1941881-B1 | Naphthalene derivatives for the treatment of dermatitis and psoriasis | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2727594-A1 | NOVEL PHARMACEUTICAL COMPOSITION | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-05-07 | — | — | EP | disclosed |
| EP-1804797-B1 | USE OF A PYRIDINE COMPOUND FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF SKIN LESIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-7868019-B2 | Dermatitis treating agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-11 | — | — | US | disclosed |
| US-7868019-B2 | Dermatitis treating agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20100130494-A1 | DERMATITIS TREATING AGENT (AS AMENDED) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130494-A1 | DERMATITIS TREATING AGENT (AS AMENDED) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-27 | — | — | US | disclosed |
| CN-101429160-A | Synthesis of 1-R-4-amino-1,2,3,4-tetrahydroquinoline | SHANGHAI PHARMATECH CO LTD (CN) | 2009-05-13 | — | — | CN | disclosed |
| US-20090069307-A1 | Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20090069307-A1 | Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-1941881-A1 | DERMATITIS REMEDIES | TANABE SEIYAKU CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| WO-2006046774-A1 | USE OF A PYRIDINE COMPOUND FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF SKIN LESIONS | TANABE SEIYAKU CO., LTD. (JP) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130494-A1 | DERMATITIS TREATING AGENT (AS AMENDED) | AOX1, TLR7, MYD88 | KDM4C 471/4885ACHE 636/4885TRPV1 225/4885 |
| US-20090069307-A1 | Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions | NQO1, TYR, NDUFB7 | KDM4C 957/4885ACHE 2304/4885TRPV1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.